Growth Metrics

Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2016 - 2024)

Palvella Therapeutics has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $575000.0 for Q4 2022.

  • Quarterly Depreciation & Amortization (CF) fell 5.58% to $575000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2022, up 12.65% year-over-year, with the annual reading at $1.9 million for FY2023, 31.26% down from the prior year.
  • Depreciation & Amortization (CF) was $575000.0 for Q4 2022 at Palvella Therapeutics, down from $767000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $845000.0 in Q1 2022 and troughed at $42000.0 in Q2 2019.
  • The 5-year median for Depreciation & Amortization (CF) is $552500.0 (2020), against an average of $438600.0.
  • Year-over-year, Depreciation & Amortization (CF) crashed 70.21% in 2019 and then soared 1161.9% in 2020.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $195000.0 in 2018, then surged by 35.9% to $265000.0 in 2019, then skyrocketed by 159.62% to $688000.0 in 2020, then dropped by 11.48% to $609000.0 in 2021, then decreased by 5.58% to $575000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Depreciation & Amortization (CF) are $575000.0 (Q4 2022), $767000.0 (Q3 2022), and $583000.0 (Q2 2022).